Updated: iRhythm Continues To Grow Despite Reimbursement, Hospital-Staffing Challenges

CMS' Decision To Punt Remote Monitoring Payment To 2023 Disappoints iRhythm Again

Despite intense lobbying from industry and physician groups, CMS chose not to install national pricing for long-term remote cardiac monitoring in its final 2022 Medicare Physician Fee Schedule Final Rule.

Zio XT Patch Side View
IRHYTHM'S ZIO XT ECG MONITOR • Source: iRhythm Technologies, Inc.

[Editor's note: This article was updated on 5 November to include comments from iRhythm's management during its 4 November earnings call.]

Remote cardiac monitoring companies must continue working with local Medicare carriers to secure higher reimbursement rates for long-term remote monitoring...

More from Policy & Regulation

More from Medtech Insight

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By 

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

European MedTech Keeps Calm Despite US Threats Of 30% Tariffs

 

MedTech Europe wants the EU to continue its commitment to reach a negotiated tariff solution with the US and measured restraint amid escalating trade tensions.

Medtech Will Benefit From Boost To EU’s Quantum Technology Initiative

 

The European Commission is focusing on how tiny particles behave to help create an EU industrial “powerhouse.”